Atossa Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atossa Therapeutics, Inc. on January 6, 2026. The Company is a Delaware corporation with its principal executive offices in Seattle, Washington. Its common stock trades on The Nasdaq Capital Market under the symbol ATOS.
Key Financial Metrics
This filing is an event-based report and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial data is included in this document.
Material Changes and Events
- Regulatory Milestone: On January 6, 2026, the U.S. Food and Drug Administration (FDA) issued a "Study May Proceed" letter for the Company's clinical study focused on metastatic breast cancer.
- Disclosure: This event is reported under Item 8.01 (Other Events) and is accompanied by a press release filed as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or a discussion of specific risks and contingencies beyond the regulatory update. The document strictly reports the FDA's authorization to proceed with the specified study.
Key Facts for Investor Verification
- Verify the specific details of the metastatic breast cancer study protocol referenced in the FDA "Study May Proceed" letter.
- Review the full text of the press release (Exhibit 99.1) for any additional context regarding the study's scope or timeline.
- Confirm the Company's current cash position and runway in the most recent 10-Q or 10-K filing, as this 8-K contains no financial data.